Zacks Research Has Positive Outlook of PBYI FY2026 Earnings

Key Points

• Zacks Research raised Puma Biotechnology’s FY2026 EPS forecast to $0.37 from $0.31, above the current consensus estimate of $0.31, while projecting FY2028 EPS of $0.45.
• Puma Biotechnology reported quarterly EPS of $0.19, beating the $0.04 analyst consensus, and revenue of $56.5 million exceeded expectations of $53 million.
• Shares opened at $9.69 after gaining 3.6%, near their 12-month high of $9.73; however, analysts maintain a consensus “Hold” rating with a $6.00 price target.

Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Investment analysts at Zacks Research boosted their FY2026 EPS estimates for shares of Puma Biotechnology in a research report issued to clients and investors on Thursday, August 27th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings of $0.37 per share for the year, up from their prior forecast of $0.31. The consensus estimate for Puma Biotechnology's current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology's Q1 2027 earnings at $0.04 EPS, Q2 2027 earnings at $0.07 EPS, Q4 2027 earnings at $0.02 EPS, FY2027 earnings at $0.14 EPS and FY2028 earnings at $0.45 EPS.

Other analysts have also recently issued research reports about the company. TD Cowen raised their price objective on Puma Biotechnology from $5.00 to $6.00 and gave the stock a "hold" rating in a research report on Friday, August 7th. Weiss Ratings raised Puma Biotechnology from a "hold (c)" rating to a "hold (c+)" rating in a report on Friday, August 21st. Finally, Wall Street Zen raised shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 15th. Two equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat, Puma Biotechnology currently has an average rating of "Hold" and a consensus price target of $6.00.

Puma Biotechnology Trading Up 3.6%

Shares of PBYI stock opened at $9.69 on Thursday. Puma Biotechnology has a 12-month low of $4.30 and a 12-month high of $9.73. The business's fifty day simple moving average is $8.46 and its 200-day simple moving average is $7.49. The company has a market cap of $500.20 million, a PE ratio of 18.63 and a beta of 1.24.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported $0.19 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.15. Puma Biotechnology had a net margin of 11.50% and a return on equity of 20.76%. The company had revenue of $56.50 million during the quarter, compared to analysts' expectations of $53.00 million.

Institutional Trading of Puma Biotechnology

Institutional investors and hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System grew its stake in Puma Biotechnology by 110.2% in the 2nd quarter. California State Teachers Retirement System now owns 4,898 shares of the biopharmaceutical company's stock valued at $40,000 after acquiring an additional 2,568 shares during the period. Wellington Management Group LLP acquired a new position in shares of Puma Biotechnology during the 2nd quarter worth about $1,023,000. Empowered Funds LLC purchased a new position in Puma Biotechnology in the 2nd quarter valued at about $1,787,000. Philadelphia Investment Partners LLC purchased a new stake in Puma Biotechnology during the 2nd quarter worth approximately $65,000. Finally, Bank of America Corp DE acquired a new position in shares of Puma Biotechnology during the second quarter valued at approximately $257,000. 61.29% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Adrian Senderowicz sold 27,000 shares of the stock in a transaction on Friday, June 12th. The shares were sold at an average price of $7.20, for a total transaction of $194,400.00. Following the sale, the director directly owned 27,000 shares of the company's stock, valued at approximately $194,400. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Douglas M. Hunt sold 8,460 shares of Puma Biotechnology stock in a transaction on Monday, July 6th. The shares were sold at an average price of $8.26, for a total transaction of $69,879.60. Following the completion of the transaction, the insider directly owned 196,841 shares of the company's stock, valued at $1,625,906.66. The trade was a 4.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 132,028 shares of company stock valued at $1,006,711 in the last 90 days. 22.20% of the stock is currently owned by insiders.

Puma Biotechnology News Summary

Here are the key news stories impacting Puma Biotechnology this week:

• Positive Sentiment: Zacks raised its FY2026 EPS forecast to $0.37 from $0.31, while increasing estimates for Q1 2027 to $0.04 from $0.03 and Q2 2027 to $0.07 from $0.06. These upgrades suggest improved near-term earnings expectations for Puma Biotechnology.
• Positive Sentiment: The FY2028 EPS forecast was lifted to $0.45 from $0.42, indicating stronger long-term profitability expectations. Zacks’ revised FY2026 estimate is also above the current-year consensus of $0.31.
• Neutral Sentiment: Despite the revisions, Zacks projects FY2027 EPS of $0.14 and Q4 2027 EPS of $0.02, reflecting modest expected profitability during portions of the forecast period. The overall outlook is therefore mixed rather than uniformly bullish.
• Negative Sentiment: Zacks cut its FY2027 EPS forecast to $0.14 from $0.18 and reduced Q4 2027 EPS to $0.02 from $0.04. These downgrades point to weaker expected earnings growth in 2027.
• Negative Sentiment: Estimates for Q3 2026 were lowered to $0.06 from $0.08, while Q3 2027 expectations fell to $0.02 from $0.05. The reductions could weigh on sentiment because they imply softer earnings in upcoming or intermediate reporting periods.

About Puma Biotechnology

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company's lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source